Tshering Dawa, Chejor Pelden
Drug Regulatory Authority, Post Box 1556, Thimphu, Bhutan.
Center for Research in Aged Care, Edith Cowan University, 270 Joondalup Dr, Joondalup, WA 6027, Australia.
Explor Res Clin Soc Pharm. 2022 Sep;7:100156. doi: 10.1016/j.rcsop.2022.100156. Epub 2022 Jul 15.
Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan was confirmed on 5 March 2020 in a 76-year-old American tourist. The national regulatory authorities have implemented varying degrees of regulatory flexibilities to prevent unnecessary death by ensuring timely access to medical products and technologies during the pandemic. The Drug Regulatory Authority of Bhutan, as a national medicines regulatory agency responsible for ensuring the quality of medical products has implemented several regulatory mechanisms to ensure access to medical products including COVID-19 vaccines during the pandemic. In this commentary, we discuss the regulatory flexibilities that ensured access to medical products and COVID-19 vaccines during the pandemic.
2019冠状病毒病(COVID-19)正在迅速演变,全球报告了数百万例病例和死亡。不丹首例COVID-19病例于2020年3月5日在一名76岁的美国游客中确诊。国家监管当局实施了不同程度的监管灵活性措施,以通过在大流行期间确保及时获得医疗产品和技术来防止不必要的死亡。不丹药品监管局作为负责确保医疗产品质量的国家药品监管机构,在大流行期间实施了多项监管机制,以确保获得包括COVID-19疫苗在内的医疗产品。在本评论中,我们讨论了在大流行期间确保获得医疗产品和COVID-19疫苗的监管灵活性措施。